[1] Takayama K, Ishida K, Matsushita T, et al. SIRT1 regulation of apoptosis of human chondrocytes[J]. Arthritis Rheum, 2009, 60(9):2731-2740.
[2] Hardie D G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy[J]. Nat Rev Mol Cell Biol, 2007, 8(10):774-785.
[3] Shah M, Kola B, Bataveljic A, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass[J]. Bone, 2010, 47(2):309-319.
[4] Mai Q G, Zhang Z M, Xu S, et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats[J]. J Cell Biochem, 2011, 112(10):2902-2909.
[5] Jeyabalan J, Shah M, Viollet B, et al. Mice lacking AMP-activated protein kinase alpha1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment[J]. J Endocrinol, 2012, 214(3):349-358.
[6] Quinn J M, Tam S, Sims N A, et al. Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function[J]. FASEB J, 2010, 24(1):275-285.
[7] Terkeltaub R, Yang B, Lotz M, et al. Chondrocyte AMP-activated protein kinase activity suppresses matrix degradation responses to proinflammatory cytokines interleukin-1beta and tumor necrosis factor alpha[J]. Arthritis Rheum, 2011, 63(7):1928-1937.
[8] Zhang Y, Vasheghani F, Li Y H, et al. Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis[J]. Ann Rheum Dis, 2015, 74(7):1432-1440.
[9] Yang C, Li Z, Lai P, et al. Chondrocyte-Specific Ablation of AMPKalpha1 Does Not Affect Bone Development or Pathogenesis of Osteoarthritis in Mice[J]. DNA Cell Biol, 2016, 35(3):156-162.
[10] Zhou S, Lu W, Chen L, et al. AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice[J]. Sci Rep, 2017, 7:43245.
[11] Gao Y, Li Y, Xue J, et al. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats[J]. Eur J Pharmacol, 2010, 635(1-3):231-236.
[12] Mankin H J. Biochemical and metabolic aspects of osteoarthritis[J]. Orthop Clin North Am, 1971, 2(1):19-31.
[13] Matsuzaki T, Matsushita T, Tabata Y, et al. Intra-articular administration of gelatin hydrogels incorporating rapamycin-micelles reduces the development of experimental osteoarthritis in a murine model[J]. Biomaterials, 2014, 35(37):9904-9911.
[14] Takayama K, Kawakami Y, Kobayashi M, et al. Local intra-articular injection of rapamycin delays articular cartilage degeneration in a murine model of osteoarthritis[J]. Arthritis Res Ther, 2014, 16(6):482.
[15] Cravedi P, Ruggenenti P, Remuzzi G. Sirolimus to replace calcineurin inhibitors? Too early yet[J]. Lancet, 2009, 373(9671):1235-1236.
[16] Bandow K, Kusuyama J, Kakimoto K, et al. AMP-activated protein kinase (AMPK) activity negatively regulates chondrogenic differentiation[J]. Bone, 2015, 74:125-133.
[17] Mccarty M F. AMPK activation--protean potential for boosting healthspan[J]. Age (Dordr), 2014, 36(2):641-663. |